Pfizer’s options market saw an extraordinary spike in activity, with its March 20 $29 put reaching a vol/OI ratio above 210 and overall daily volume jumping to 1.39× the 30-day average—the highest since mid-December.

Oncology sales lifted by the Seagen acquisition and BRAFTOVI combinations drove a 7% revenue increase in the first nine months, even as total quarterly revenues declined ~5.9% year-over-year. Full-year 2025 revenues are guided near $62 billion. EPS growth remains strong, but nearly full payout ratios and a 26.6-point drop in free-cash-flow margins over five years constrain reinvestment capacity.

Patent expirations threaten roughly $1.5 billion in revenue as key drugs like Eliquis lose exclusivity, while regulatory price caps under U.S. government agreements and European cost-containment measures limit drug price increases. Tariff uncertainty from the Trump administration has eased following a 2025 deal, but legal risks from Bayer’s mRNA patent litigation and intensified competition in weight-management and oncology markets add pressure. Strategic exclusive licensing and biomolecular AI collaborations aim to secure R&D autonomy and offset these external constraints.

Investors are cautiously optimistic about Pfizer’s long-term turnaround, drawn by deep valuation discounts, AI-driven research partnerships, acquisitions in oncology and obesity, and promising trial readouts, though near-term skepticism lingers amid patent expirations, revenue and EPS declines, and uncertainty on when a rebound will materialize.